Home > Boards > US Listed > Biotechs >

Mind Medicine (MindMed) Inc (MNMD)

MNMD RSS Feed
Add MNMD Price Alert      Hide Sticky   Hide Intro
Moderator: DarthYoda, BubbaInSC, PyroStocks, Wolf-man jack
Search This Board: 
Last Post: 5/18/2022 5:47:43 PM - Followers: 188 - Board type: Free - Posts Today: 21

 

 

 
 
Industry: Psychedelic Medicine / Digital Therapeutics / Biotechnology

Location: New York, NY / Toronto, Ontario

Flagship Products: 18-MC, Project LucyAlbert Digital Medicine

Treatment Focus: Addiction, ADHD, Anxiety, Depression, Headaches

Ticker: $MNMD (NASDAQ), $MMED (NEO), $MMQ (DAX),

Financial ReportsLink

SEC FilingsLink

SEDAR FilingsLink


 

COMPANY OVERVIEW

MindMed is an early stage biotechnology company founded in 2019, and headquartered in New York City. They are focused on discovering, developing and deploying psychedelic based medications and treatment protocols, primarily derived from Psilocybin, LSD, MDMA, DMT and Ibogaine. The company is led by Chief Executive Officer and Co-Founder, JR Rahn, a former Silicon Valley tech executive, and President and Board Director, Dr. Miri Halperin Wernli, a thirty year pharmaceutical and biomedical executive who previously served at several major pharmaceutical companies, such as Merck, Roche, and Actelion. Their pipeline is focused on treating a range of common mental health and neurological disorders, such as addiction, anxiety, depression, and headaches.

 


PRODUCTS AND SERVICES
 

Our Robust and Diverse Development Pipeline - Pipeline Diversification Offers Access To Full Potential Of Psychedelic Inspired Medicines

 

MindMed engages in the research and development of medications and treatments derived from LSD, Psilocybin, MDMA, DMT, and Ibogaine.

18-MC: 18-Methoxycoronaridine is a novel derivative of Ibogaine, a naturally occurring psychoactive substance found in plants, which has demonstrated promising results in treating drug, alcohol, and nicotine addiction. 18-MC has a significantly improved safety profile, and is shown to be neither psychoactive nor psychedelic. At MindMed, 18-MC is currently entering Phase 2A trials for the treatment of opioid addiction.

Project Lucy: This program intends to develop and commercialize psychedelic assisted therapies for the treatment of anxiety disorder. Experimental doses of LSD will be evaluated under supervision, and in coordination with ongoing patient therapies. In December of 2020, MindMed announced the successful completion of a Pre-IND meeting with the FDA for Project Lucy, as well as preparations to open an Investigational New Drug (IND) in August of 2021, with a Phase 2B clinical trial for LSD assisted therapy.

Albert Digital Medicine: Digital therapeutics are evidence based interventions guided by software for the treatment and prevention of diseases and disorders. These digital tools include wearable devices, machine learning, and AI systems. Albert is an early stage platform intended to develop a comprehensive toolset focused on delivering psychedelic based treatments and therapies in combination with digital therapeutics. Dr. Miri Halperin Wenli, MindMed’s President and Head of Chair of Technology Evaluation, is currently designing an experimental clinical trial that pairs psychedelic inspired medicines, such as LSD, with digital therapeutics to track, engage, and influence patient behavior.


DEVELOPMENT AND COMMERCIALIZATION

MindMed’s pathway to commercialization is a standard three stage process of Discovering, Developing, and Deploying. Initially, research will focus on acquiring and discovering new chemical products and treatment protocols. These compounds and protocols will enter FDA regulated clinical trials, with an effort to secure partnerships with major pharmaceutical companies. Finally, strategic affiliations with research centers, hospitals, pharmaceutical companies, and insurers will enable the licensing of medications and protocols. It is important that we monitor how their commercialization strategy develops, because psychedelic inspired treatments are new products, and it’s unclear how well they can be monetized.


SUCCESS STORIES: WHY SPRAVATO’S FDA APPROVAL MATTERS

On August 3rd, 2020, The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the FDA had approved SPRAVATO (eskatamine), the first prescription nasal spray, for the treatment of depressive symptoms in adults with major depressive disorder, and treatment-resistant depression.

Spravato is a potent sterioisomer of ketamine, a psychedelic substance used in anesthesia, pain management, depression, and seizures. Spravato is significant for two important reasons. It represents the first FDA approved drug for depression that does not work directly on monoamines, and it is the first psychedelic drug approved by the FDA for a psychiatric condition. This demonstrates the utility of psychedelic substances, and supports the need for further research and development.


PARTNERSHIPS

MindMed currently maintains several clinical and research partnerships.

1. Partnership with Swiss psychedelic drug discovery startup, Mindshift Compounds AG, for the purpose of developing and patenting next-generation psychedelic compounds.

2. Partnership with New York University Langone Medical Center, for the purpose of launching a clinical training program focused on psychedelic assisted therapies and medications.

3. Partnership with Liechti Lab, a psychopharmacological research center based in Switzerland, for the purpose of research and development into the effects and state of consciousness induced by psilocybin and LSD.

4. Partnership with Maastricht University, based in the Netherlands, for the purpose of conducting clinical trials for the use of LSD in adult patients with ADHD.


 

IN THE MEDIA

”Could the Embrace of Psychedelics Lead to a Mental-Health Revolution?”Vogue

”Psychedelics-Drug Startup Raises $24 Million Ahead of IPO”Wall Street Journal

”Silicon Valley’s psychedelic wonder drug is almost here”Fast Company

”Psychedelic drug company MindMed applies for nasdaq up-listing”Forbes

”Psychedelic drugs may transform mental health care. And big business is ready to profit from the revolution”Fortune

”A startup that wants to use psychedelics to treat addiction just raised $6.2 million from the host of Shark Tank and the architect behind the world’s biggest cannabis grower”Business Insider

”New York is getting its first psychedelic-medicine center, with the help of a startup called MindMed, which develops hallucinogens to treat mental illness and addiction, and is funding an institute at N.Y.U. Langone Medical Center”The New Yorker

”MindMed surges, putting it at the forefront of psychedelic euphoria”Bloomberg


 





 

 

MNMD
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MMEDF News: Quarterly Report (10-q) 05/16/2022 04:23:17 AM
MMEDF News: Current Report Filing (8-k) 05/16/2022 04:17:51 AM
MMEDF News: Additional Proxy Soliciting Materials (definitive) (defa14a) 05/13/2022 12:28:45 PM
MMEDF News: Securities Registration Statement (simplified Form) (s-3) 05/04/2022 02:01:50 AM
MMEDF News: Statement of Changes in Beneficial Ownership (4) 04/27/2022 01:10:51 PM
PostSubject
#8087  Sticky Note MORE DILUTION DILUTION DILUTION Update MAY 17, 2022 Wolf-man jack 05/17/22 11:20:18 PM
#7935  Sticky Note MindMed Reports Full Year 2021 Financial Results and PyroStocks 03/28/22 04:29:01 PM
#7425  Sticky Note Companion bills filed by Sen. Bill Cassidy (R-LA) DarthYoda 12/22/21 02:52:45 PM
#8108   Congress hasn't been holding back the cannabis sector, DarthYoda 05/18/22 05:47:43 PM
#8107   Just put these two lengthy excerpts together... DarthYoda 05/18/22 04:51:25 PM
#8106   No one is saying MNMD needs any particular DarthYoda 05/18/22 03:48:36 PM
#8105   Can you all really read pages 32-37 of DarthYoda 05/18/22 03:27:28 PM
#8104   I like how you think PyroStocks 05/18/22 02:53:58 PM
#8103   Correct. All that crap about congress and bills Money $hot 05/18/22 02:35:44 PM
#8102   WQLF SAYS ; New Yearly LOW today for Wolf-man jack 05/18/22 01:43:35 PM
#8101   MindMed has suggested talks have been fairly smooth PyroStocks 05/18/22 01:09:51 PM
#8100   This is really interesting - thank you for PyroStocks 05/18/22 01:09:08 PM
#8099   Topic Trend-"Psychedelic Therapy": DarthYoda 05/18/22 12:30:26 PM
#8098   United States Patent Application Publication Pub . No DarthYoda 05/18/22 11:39:52 AM
#8097   "Structure-activity Relation of Halogenated 2,5-Dimethoxyamphetamines Compared t DarthYoda 05/18/22 10:59:51 AM
#8096   "Monoamine Receptor and Transporter Interaction Profiles of 4-Alkyl-Substituted DarthYoda 05/18/22 10:44:10 AM
#8095   WQLF REPLIES; That’s a Good thing YQU now Wolf-man jack 05/18/22 10:14:06 AM
#8094   Simply put, the Feds have to pass the DarthYoda 05/18/22 10:03:39 AM
#8093   I will buy in again at .50 or 49andretired 05/18/22 09:50:46 AM
#8092   GOOD LUCK with those BILLS. The BIG PHARMA Wolf-man jack 05/18/22 09:34:58 AM
#8091   I was looking at the text of the DarthYoda 05/18/22 09:18:31 AM
#8090   Acquisition? TOO FUNNY YQU Understand. Good Luck with Wolf-man jack 05/18/22 09:07:35 AM
#8089   Totally agree with you on this. Sound investment PyroStocks 05/18/22 08:49:01 AM
#8088   I wasn't trying to spin it either way DarthYoda 05/18/22 05:31:39 AM
#8087   MORE DILUTION DILUTION DILUTION Update MAY 17, 2022 Wolf-man jack 05/17/22 11:20:18 PM
#8086   That's how I'm viewing it. Non issue. PyroStocks 05/17/22 07:52:14 PM
#8085   Just so it's in place legally to do PyroStocks 05/17/22 07:51:19 PM
#8084   They have a lot of clinical trials going Jack Torrance 05/17/22 04:31:41 PM
#8083   I don't think it makes sense to have DarthYoda 05/17/22 03:19:14 PM
#8082   I believe this post from earlier in the PyroStocks 05/17/22 03:14:04 PM
#8081   Based on this comment, what do you think DarthYoda 05/17/22 02:47:08 PM
#8080   I addressed all the points you tried to DarthYoda 05/17/22 02:36:03 PM
#8079   How is a bill that federally streamlines psychedelic DarthYoda 05/17/22 01:56:39 PM
#8078   Sideways until year end... then it will take off. PyroStocks 05/17/22 11:09:06 AM
#8077   The last time I was here, about a GE_Jim 05/17/22 10:18:30 AM
#8076   Down the rabbit hole stuff Money $hot 05/17/22 09:55:27 AM
#8075   May 2022 Investor Deck PyroStocks 05/17/22 09:16:38 AM
#8074   QK Wolf Let's Meet in the middle: PyroStocks 05/17/22 09:15:03 AM
#8073   I just simply do not agree with you... PyroStocks 05/17/22 09:08:04 AM
#8072   WQLF SAYS; What is also means there are Wolf-man jack 05/17/22 09:03:41 AM
#8071   It is important to realize that stock dilution PyroStocks 05/17/22 09:00:30 AM
#8070   What else is interesting is this: "No offering PyroStocks 05/17/22 08:56:24 AM
#8069   What it Means is MORE DILUTION DILUTION DILUTION Wolf-man jack 05/17/22 08:54:30 AM
#8068   This means to me that some good news PyroStocks 05/17/22 08:48:22 AM
#8067   ATM financing strategies provide control on the timing PyroStocks 05/17/22 08:47:35 AM
#8066   1.) Ask and Ye shall receive... DarthYoda 05/16/22 09:05:10 PM
#8064  Restored Do you believe that post is relevant or Money $hot 05/16/22 01:18:37 PM
#8063   MindMed Reports First Quarter 2022 Financial Results and PyroStocks 05/16/22 10:39:45 AM
#8062   MindMed believes its available cash will be sufficient PyroStocks 05/16/22 10:39:09 AM
#8061   Been stockpiling since inception. Gonna be fun when PyroStocks 05/14/22 08:36:26 PM
#8059   Definitely keeping the faith. Been slowly Sideem 05/13/22 07:29:24 PM
#8055   $.7011 as Get Smart would say. MNMD MIndGames Wolf-man jack 05/12/22 10:17:39 AM
#8054   Take advantage of the MIndMed Games Dilemma YQU Wolf-man jack 05/12/22 10:05:11 AM
PostSubject
Consent Preferences